{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhang X"],"funding":["Nature Science Foundation of China","National High Technology Research and Development Program of China","National Key Basic Research Program of China","PKU People’s Hospital Research and development Funding"],"pagination":["19"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5436452"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14"],"pubmed_abstract":["AIM:The Xiaoke Pill containing Chinese herb extracts and Glibenclamide, is used in therapy for type 2 diabetes mellitus (T2DM), and is effective in reducing the risk of hypoglycemia and improving diabetes symptoms compared with Glibenclamide. We describe a quantitative proteomics project to measure the T2DM serum proteome response to the Xiaoke Pill and Glibenclamide. METHODS:Based on a recently conducted 48-week clinical trial comparing the safety and efficacy of Glibenclamide (n = 400) and Xiaoke Pill (n = 400), after matching for age, sex, BMI, drug dose and whether hypoglycemia occurred, 32 patients were selected for the serum based proteomic analysis and divided into four groups (with/without hypoglycemia treated with Xiaoke Pill or Glibenclamide, n = 8 for each group). We screened th"],"journal":["Clinical proteomics"],"pubmed_title":["The serum protein responses to treatment with Xiaoke Pill and Glibenclamide in type 2 diabetes patients."],"pmcid":["PMC5436452"],"funding_grant_id":["Nature Science Foundation of China","RD 2013-13","No.2010CB912703","No.2006AA02A409"],"pubmed_authors":["Wang Q","Zhang X","Ji L","Lou X","Paul SK","Wen B","Liu S","Sun H","Hou G"],"additional_accession":[]},"is_claimable":false,"name":"The serum protein responses to treatment with Xiaoke Pill and Glibenclamide in type 2 diabetes patients.","description":"AIM:The Xiaoke Pill containing Chinese herb extracts and Glibenclamide, is used in therapy for type 2 diabetes mellitus (T2DM), and is effective in reducing the risk of hypoglycemia and improving diabetes symptoms compared with Glibenclamide. We describe a quantitative proteomics project to measure the T2DM serum proteome response to the Xiaoke Pill and Glibenclamide. METHODS:Based on a recently conducted 48-week clinical trial comparing the safety and efficacy of Glibenclamide (n = 400) and Xiaoke Pill (n = 400), after matching for age, sex, BMI, drug dose and whether hypoglycemia occurred, 32 patients were selected for the serum based proteomic analysis and divided into four groups (with/without hypoglycemia treated with Xiaoke Pill or Glibenclamide, n = 8 for each group). We screened th","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017","modification":"2025-04-04T08:13:00.308Z","creation":"2019-03-27T02:45:18Z"},"accession":"S-EPMC5436452","cross_references":{"pubmed":["28529466"],"doi":["10.1186/s12014-017-9154-0"]}}